Yanhuai R. Ding

TL;DR: The discovery of DC371739, an indole-containing tetrahydroisoquinoline compound with promising lipid-lowering effects, and its combination with atorvastatin treatment to additively improve dyslipidemia, while providing a potential alternative therapeutic strategy for individuals with statin intolerance.

TL;DR: There were no clinically relevant differences in HSK3486 exposure or PD in subjects with mild or moderate hepatic impairment compared to subjects with normal hepatic function and these data imply that HSK 3486 dose adjustment is not warranted in subjectswith mild ormoderate hepatic impairments.

TL;DR: ABI-H2158 in cHBV patients following 14 days of dosing was well tolerated and demonstrated potent antiviral activity, and safety and pharmacokinetics supported future QD dosing.

TL;DR: GST-HG131 exhibited an acceptable safety profile in healthy subjects at single doses ranging from 10-300 mg and multiple doses (BID) ranging from 30-60‬mg, and the MAD doses that potentially meet the therapeutic AUC requirements imply GST- HG131 has potential as a therapeutic option for CHB infection.